VISITING HOSPITAL

Hospital visitors must wear a medical paper face mask. Fabric face coverings are not acceptable. Expand this message for more detailed information about hospital visiting guidelines.

Last updated:
16 September 2022

 

Mask exemptions accepted for people seeking treatment
Any member of the public with a mask exemption is welcome in all our facilities when attending to receive health care and *treatment. Please show your mask exemption card and appointment letter to staff at the entrance.

*Treatment includes: coming into the Emergency Department, outpatient appointments,  surgery or a procedure.

For visitors to all facilities effective from Friday 16 September 2022

Some visitor restrictions for all Te Whatu Ora Waitaha Canterbury hospitals and health facilities remain in place, but we have relaxed others.

There is still a heightened risk to vulnerable people in hospital and so people must continue to wear a mask when visiting any of our facilities and follow other advice designed to keep patients, staff and  visitors safe.

Kia whakahaumaru te whānau, me ngā iwi katoa – this is to keep everybody safe:

  • Visitors or support people must not visit our facilities if they are unwell. Do not visit if you have recently tested positive for COVID-19 and haven’t completed your isolation period.
  • Patients may have more than one visitor, except in some situations such as multi-bed rooms where it can cause overcrowding.
  • Surgical/medical masks must be worn at all sites. Masks will be provided if you don’t have one.
  • For Specialist Mental Health Services everyone is strongly encouraged to wear a surgical mask in all inpatient areas and areas where consumers are receiving care (i.e. community appointments, home-visits, transporting people). Discretion may be applied in cases where masks impair your ability to communicate effectively.
  • Visitors must not eat or drink in multibed rooms because of the increased risk when multiple people remove their mask in the same space.
  • Hand sanitiser is available and must be used.

Thank you in advance for your patience and understanding as our staff work hard to protect and care for some of the most vulnerable in our community.

Visiting patients with COVID-19

  • People can visit patients who have COVID-19 but they must wear an N95 mask – this will be provided if you don’t have one.
  • Other methods of communication will be facilitated e.g. phone, Facetime, Zoom, WhatsApp etc where visits aren’t possible.

All of our Hospitals

Visiting hours for our hospitals have returned to pre COVID-19 hours with the exception of Christchurch Women’s Hospital.

All visitors must wear a medical mask.

Parents/caregivers are able to be with their child in hospital and visitors are now allowed, except for the Children’s Haematology and Oncology Day stay where just one parent/caregiver is able to attend their appointment with their child. Exceptions by special arrangement only.

Patients and visitors should also read the additional more detailed visiting guidelines for each specific hospital.

More COVID-19 information

Measles outbreak 2019

Official information request details

  1. Cases of measles, were found to be caused by vaccine strains, yet there was no clarification of what those vaccine strains were. What were those strains? 38 case were wild strains. What were the additional wild strains, apart from B3?
  2. Am I to understand that the 13 vaccine strains were from the GSK Priorix MMR vaccine? As these developed symptoms recently, I would presume that to be the case. Given the numbers that vaccine strain were detected in, have resulted in measles infection, will there be any recalls of the batches involved? Were they considered to be potentially hot batches? Were those cases all from the same batch and where do those 13 cases of vaccine strain fit in, to the data on the ESR website? I am somewhat confused, as the CDHB site states, these are not included in the outbreak... yet surely need to be stated on the ESR site somewhere and more detail provided? That would be interpreted as an act of transparency, would it not?
    NB: There is evidence in the scientific community that measles vaccine strain, can be transmitted to others from someone who was twice vaccinated with the MMR vaccine. The index case i.e. the fully vaccinated person, transmitted to other partially and fully MMR vaccinated individuals. Therefore the potential for transmission is not theoretical.
  3. What assurances will you be offering to the public who have received the GSK vaccine, who also may experience vaccine strain measles? Could more people be experiencing symptoms, but having had the vaccine, not notify anyone, believing that they were protected? If so, could these also be potentially vaccine strain cases, therefore your number of 13, be higher in fact?
  4. Given that there is evidence of the vaccine virus being capable of being transmitted to others, in the scientific literature, what public notification will the CDHB be offering, if at all, to inform about this, as this has ramifications for Community Immunity, as well as the process of Informed consent, under risks and benefits, does it not?
  5. By excluding the 13 cases from the outbreak, this may confuse the public and result in a lack of confidence in the vaccine itself and given that the Mayo Clinic's own vaccine scientist, Dr Gregory Poland has himself stated in Pub Med papers, that measles is becoming a disease of the vaccinated and that a new vaccine is needed, does this not raise some concerns for the CDHB?
  6. How many of the cases that are listed on the ESR website who were under 15 months of age and also above 15 months of age and under 4 years old, were in fact NOT being breastfed, which may have afforded them maternal transfer of antibodies and therefore protection? How many of those mothers had been vaccinated in the past, with the MMR vaccine, whose infants contracted measles?
  7. If 236 people who notified the authorities were investigated, what specific investigations were undertaken, as I was informed by ESR, that not all cases were investigated by lab testing, and some were confirmed by association only? I note that Hospitalisations are listed on ESR database. This would not presumably indicate how many were actually 'admitted,' to a ward, with a proportion of those spending about 3 hours on average in the Accident and Emergency Department, before being sent home. Some people attend the hospital in order to avoid the expense of the After Hours of course, or incurring a charge for attending their GP clinic.
  8. If those who were confirmed as having measles by reliable lab testing and to have 'vaccine strain measles' which will not be included in the outbreak, how many of their contacts who also developed measles, were tested by the RT-PCR test, to determine if they also had vaccine strain measles?
  9. Why has GSK not been mentioned in the CDHB information, in regard to the 13 vaccine strain cases? That was one of my questions in the OIA. Are they notified about these cases?
  10. Will the vaccine strain cases be reported to NZ CARM and reported on both databases? Do you consider this to be a vaccine failure, measles, or an adverse reaction?
  11. When will the media and the wider public be informed about the genotype results? They are not found easily when one goes to the site.
  12. What are those who had vaccine strains actually told? Will the fact that they have experienced a milder form of measles, result in any type of 'cell mediated immunity' and what strains will they be immune to? Is there any likelihood that there could be a problem with mutations for those people?
  13. Given that the numbers of cases who have been infected is just 38 wild strain and 13 vaccine strain cases and a significant number of those would not have been of an age, when they would be administered the vaccine due to their age, whilst others were either partially or fully vaccinated with the MMR vaccine, yet still contracted measles, what do you see this latest information suggests, about Community Immunity and how this vaccine is perceived, regarding its efficacy and the science that is evolving, around Adversomics and Genomics, both being integral parts of immune response and best health outcomes?
  14. Will all other DHBs be providing the same type of information on genotyping of cases on their websites, as that collated information becomes available?

Tags

Download pdf (800KB)

Back to Document Library

Page last updated: 23 July 2019

Is this page useful?